Skip to main content

Imfinzi Side Effects

Generic name: durvalumab

Medically reviewed by Last updated on Feb 6, 2023.

Note: This document contains side effect information about durvalumab. Some dosage forms listed on this page may not apply to the brand name Imfinzi.

Applies to durvalumab: intravenous solution.

Serious side effects of Imfinzi

Along with its needed effects, durvalumab (the active ingredient contained in Imfinzi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking durvalumab:

More common

  • Bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or cloudy urine
  • body aches or pain
  • chest pain or tightness
  • chills
  • cough
  • depressed mood
  • difficult, burning, or painful urination
  • difficulty having a bowel movement
  • dry skin and hair
  • ear congestion
  • feeling cold
  • fever
  • frequent urge to urinate
  • general feeling of discomfort or illness
  • headache
  • hoarseness, husky, or loss of voice
  • lower back or side pain
  • muscle cramps and stiffness
  • nervousness
  • runny or stuffy nose
  • sensitivity to heat
  • slowed heartbeat
  • sneezing
  • sore throat
  • stomach cramps
  • sweating
  • tenderness
  • thickening of bronchial secretions
  • tingling of the hands or feet
  • trouble breathing
  • trouble sleeping
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • watery or bloody diarrhea

Less common

  • Back, leg, or stomach pains
  • black, tarry stools
  • bleeding gums
  • bloody nose
  • blurred vision or other changes in vision
  • dark urine
  • eye redness, irritation, or pain
  • general body swelling
  • heavier menstrual periods
  • light-colored stools
  • loss of appetite
  • nausea
  • nosebleeds
  • pale skin
  • pinpoint red spots on the skin
  • sensitivity of the eye to light
  • skin rash
  • stiff neck or back
  • tearing
  • unusual bleeding or bruising
  • upper right abdominal or stomach pain
  • vomiting
  • yellow eyes and skin


  • Blistering, peeling, or loosening of the skin
  • dizziness
  • drowsiness
  • fainting
  • joint or muscle pain
  • red skin lesions, often with a purple center
  • sores, ulcers, or white spots in the mouth or on the lips
  • swollen glands

Other side effects of Imfinzi

Some side effects of durvalumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Constipation
  • lack or loss of strength
  • loss or thinning of the hair

For Healthcare Professionals

Applies to durvalumab: intravenous solution.


Common (1% to 10%): Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism)[Ref]


Very common (10% or more): Rash (dermatitis, dermatitis acneiform, dermatitis psoriasiform, psoriasis, rash maculopapular, rash pruritic, rash papular, rash pustular, skin toxicity, eczema, erythema, erythema multiforme, rash erythematous, acne, lichen planus) (11%)[Ref]


Uncommon (0.1% to 1%): Immune-related myocarditis[Ref]


Very common (10% or more): Lymphopenia (11%)

Common (1% to 10%): Anemia[Ref]


Very common (10% or more): Urinary tract infection (e.g., cystitis, candiduria, urosepsis) (15%)[Ref]


Very common (10% or more): Constipation (21%), nausea (16%), abdominal pain (upper, lower, flank) (14%), diarrhea/colitis (13%)

Common (1% to 10%): Dehydration

Frequency not reported: Immune-mediated colitis[Ref]


Common (1% to 10%): Liver injury, immune-mediated hepatitis

Uncommon (0.1% to 1%): Increased ASO, increased ALT, hyperbilirubinemia

Frequency not reported: Immune-mediated hepatitis[Ref]


Very common (10% or more): Decreased appetite/hypophagia (19%), hyponatremia (12%)

Common (1% to 10%): Deterioration of general physical health, increased alkaline phosphatase, hypermagnesemia, hypercalcemia, hyperglycemia, neutropenia, hyperkalemia, hypoalbuminemia[Ref]


Common (1% to 10%): Infusion-related reactions[Ref]


Common (1% to 10%): Infections (e.g., sepsis, necrotizing fasciitis, osteomyelitis)[Ref]


Uncommon (0.1% to 1%): Uveitis and keratitis[Ref]


Very common (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal chest pain, musculoskeletal pain and discomfort, myalgia, neck pain) (24%)[Ref]

Nervous system

Common (1% to 10%): Pyrexia/tumor associated fever

Uncommon (0.1% to 1%): Immune-related aseptic meningitis[Ref]


Very common (10% or more): Fatigue (e.g., asthenia, lethargy, malaise) (39%), peripheral edema (e.g., edema, localized edema, edema peripheral, lymphedema, peripheral swelling, scrotal edema, scrotal swelling) (15%), pyrexia/tumor associated fever (14%)

Common (1% to 10%): Embryofetal toxicity[Ref]


Common (1% to 10%): Acute kidney injury, increased creatinine[Ref]


Very common (10% or more): Dyspnea/exertional dyspnea (24%), cough/productive cough (10%)

Uncommon (0.1% to 1%): Immune-mediated pneumonitis[Ref]

Frequently asked questions


1. Product Information. Imfinzi (durvalumab). Astra-Zeneca Pharmaceuticals. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.